Patent Assignment
Reel/Frame 050216/0254
Assignment of Assignor's Interest
Recorded: 2019-08-29
Pages: 6
Assignor
ELWHA LLC
Executed: 2019-08-29
Assignee
THE INVENTION SCIENCE FUND II, LLC
3150 139TH AVE SE, BELLEVUE, WASHINGTON, 98005
Covered Properties
(21)
Compositions and Methods Including B Lymphocyte Cell Line Expressing Membrane Immunoglobulin Different from Secreted Immunoglobulin
PCT:
PCT/US2012/070840 ↗
Compositions, Methods, and Computer Systems Related to Making and Administering Modified T Cells
PCT:
PCT/US2014/023650 ↗
Compositions and Methods Including B Lymphocyte Cell Line Expressing Membrane Immunoglobulin Different from Secreted Immunoglobulin and Cytolytic Function
PCT:
PCT/US2017/036521 ↗
Compositions and Methods for Modified B Cells Expressing Reassigned Biological Agents
PCT:
PCT/US2019/022572 ↗
Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including an Exogenously Incorporated Nucleic Acid Expressing an Exogenous Membrane Immunoglobulin Reactive to a First Antigen and Including an Endogenous Gene Expressing an Endogenous Secreted Immunoglobulin Reactive to a Second Antigen
Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including at Least One Endogenous Gene Expressing at Least One Endogenous Membrane Immunoglobulin Reactive to a First Antigen and Including at Least One Exogenously Incorporated Nucleic Acid Expressing at Least One Exogenous Secreted Immunoglobulin Reactive to a Second Antigen
Compositions, Methods, and Computer Systems Related to Making and Administering Modified T Cells
Compositions, Methods, and Computer Systems Related to Making and Administering Modified T Cells
Application:
13/826,803 →
Publication:
US 2014/0274801
Compositions, Methods, and Computer Systems Related to Making and Administering Modified T Cells
Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including an Exogenously Incorporated Nucleic Acid Expressing an Exogenous Membrane Immunoglobulin Reactive to a First Antigen and Including an Endogenous Gene Expressing an Endogenous Secreted Immunoglobulin Reactive to a Second Antigen
Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including an Exogenously Incorporated Nucleic Acid Expressing an Exogenous Membrane Immunoglobulin Reactive to a First Antigen and Including an Endogenous Gene Expressing an Endogenous Secreted I
Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including an Exogenously Incorporated Nucleic Acid Expressing an Exogenous Membrane Immunoglobulin Reactive to a First Antigen and Including an Endogenous Gene Expressing an Endogenous Secreted I
Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including at Least One Endogenous Gene Expressing at Least One Endogenous Membrane Immunoglobulin Reactive to a First Antigen and Including at Least One Exogenously Incorporated Nucleic Acid Expr
Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including at Least One Endogenous Gene Expressing at Least One Endogenous Membrane Immunoglobulin Reactive to a First Antigen and Including at Least One Exogenously Incorporated Nucleic Acid Expressing at Least One Exogenous Secreted Immunoglobulin Reactive to a Second Antigen
Compositions and Methods Including Cytotoxic B Lymphocyte Cell Line Expressing Exogenous Membrane Immunoglobulin Different from Secreted Immunoglobulin
Compositions, Methods, and Computer Systems Related to Making and Administering Modified T Cells
Compositions, Methods, and Computer Systems Related to Making and Administering Modified T Cells
Application:
15/498,780 →
Publication:
US 2017/0224735
Compositions and Methods for Modified B Cells Expressing Reassigned Biological Agents
Compositions, Methods, and Computer Systems Related to Making and Administering Modified T Cells
Application:
16/205,556 →
Publication:
US 2019/0091263
Compositions and Methods Including Cytotoxic B Lymphocyte Cell Line Expressing Exogenous Membrane Immunoglobulin Different from Secreted Immunoglobulin
Compositions and Methods for Modified B Cells Expressing Reassigned Biological Agents
Related Assignments
(15)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Mar 13, 2012
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.
To: ELWHA LLC
Reel/Frame 027855/0763 →
Assignment of Assignor's Interest
Mar 13, 2012
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.
To: ELWHA LLC
Reel/Frame 027854/0193 →
Assignment of Assignor's Interest
Nov 11, 2013
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.; MCKNIGHT, GARY L.
To: ELWHA LLC
Reel/Frame 031576/0133 →
Assignment of Assignor's Interest
Nov 11, 2013
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.; MCKNIGHT, GARY L.
To: ELWHA LLC
Reel/Frame 031577/0307 →
Assignment of Assignor's Interest
Nov 11, 2013
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.; MCKNIGHT, GARY L.
To: ELWHA LLC
Reel/Frame 031576/0361 →
Assignment of Assignor's Interest
Apr 6, 2015
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.
To: ELWHA LLC
Reel/Frame 035339/0238 →
Assignment of Assignor's Interest
Apr 13, 2015
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.
To: ELWHA LLC
Reel/Frame 035393/0524 →
Assignment of Assignor's Interest
Apr 13, 2015
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.
To: ELWHA LLC
Reel/Frame 035393/0346 →
Assignment of Assignor's Interest
Aug 18, 2015
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.
To: ELWHA LLC
Reel/Frame 036345/0948 →
Assignment of Assignor's Interest
Aug 18, 2015
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.
To: ELWHA LLC
Reel/Frame 036346/0594 →
Assignment of Assignor's Interest
Oct 17, 2016
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.; MCKNIGHT, GARY L.
To: ELWHA LLC
Reel/Frame 040029/0687 →
Assignment of Assignor's Interest
Jun 8, 2018
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.; MCKNIGHT, GARY L.
To: ELWHA LLC
Reel/Frame 046031/0524 →
Assignment of Assignor's Interest
Nov 13, 2019
From: THE INVENTION SCIENCE FUND II, LLC
To: KOTA BIOTHERAPEUTICS, LLC
Reel/Frame 050995/0470 →
Assignment of Assignor's Interest
Jan 29, 2020
From: THE INVENTION SCIENCE FUND II, LLC
To: KOTA BIOTHERAPEUTICS, LLC
Reel/Frame 051661/0108 →
Assignment of Assignor's Interest
May 6, 2021
From: KOTA BIOTHERAPEUTICS, LLC
To: THE INVENTION SCIENCE FUND II, LLC
Reel/Frame 056159/0064 →